In breast cancer, there is no clinical studies focusing on the immunoregulatory effects of mTOR inhibitors so far; only a preclinical study found that everolimus decreased the number of CD8+ T cells but had no effect on CD4+ T and natural killer (NK) cells in four T1 tumor-bearing mice compared to the control group [18]. This evidence concerns the gene CD4 and breast carcinoma.